A study found significant incidence of advanced neoplasia in patients who had a colonoscopy to screen for colorectal cancer (CRC) when aged more than 75 years. The incidence of CRC is known to ...
Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...
Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...
The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s RNA-based colorectal cancer (CRC) screening test, ColoSense. The new kit enhances user ...
Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
Presenting patients with a choice of screening options didn’t result in more patients getting screened for colorectal cancer, according to a study published in JAMA Network Open. Researchers examined ...